NASDAQ: ORGO
Organogenesis Holdings Inc Stock

$2.43+0.00 (+0%)
Updated Jun 26, 2026
ORGO Price
$2.43
Fair Value Price
$0.25
Market Cap
$312.68M
52 Week Low
$2.04
52 Week High
$7.08
P/E
-16.2x
P/B
1.28x
P/S
0.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$514.70M
Earnings
$2.72M
Gross Margin
72.9%
Operating Margin
0.58%
Profit Margin
-3.6%
Debt to Equity
0.57
Operating Cash Flow
$31M
Beta
1.65
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A

ORGO Overview

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ORGO's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
ORGO
Ranked
#48 of 50

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important ORGO news, forecast changes, insider trades & much more!

ORGO News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ORGO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ORGO ($2.43) is overvalued by 866.93% relative to our estimate of its Fair Value price of $0.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ORGO ($2.43) is not significantly undervalued (866.93%) relative to our estimate of its Fair Value price of $0.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORGO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORGO due diligence checks available for Premium users.

Valuation

ORGO fair value

Fair Value of ORGO stock based on Discounted Cash Flow (DCF)

Price
$2.43
Fair Value
$0.25
Overvalued by
866.93%
ORGO ($2.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORGO ($2.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORGO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ORGO price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-16.2x
Industry
-4.67x
Market
12.39x

ORGO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.28x
Industry
1.55x
ORGO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ORGO's financial health

Profit margin

Revenue
$37.2M
Net Income
-$53.2M
Profit Margin
-150.9%
ORGO's Earnings (EBIT) of $2.96M... subscribe to Premium to read more.
Interest Coverage Financials
ORGO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$520.0M
Liabilities
$138.6M
Debt to equity
0.57
ORGO's short-term assets ($268.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORGO's short-term assets ($268.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORGO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORGO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$21.1M
Investing
-$3.1M
Financing
-$20.2M
ORGO's operating cash flow ($30.75M)... subscribe to Premium to read more.
Debt Coverage Financials

ORGO vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ORGOD$312.68M0.00%-16.20x1.28x
TKNOC$308.28M+5.31%-17.97x4.75x
SIGAC$281.16M-0.76%13.52x1.85x
CGCD$399.36M+3.61%-1.48x0.79x
KMDAC$418.80M+1.11%20.74x1.61x

Organogenesis Holdings Stock FAQ

What is Organogenesis Holdings's quote symbol?

(NASDAQ: ORGO) Organogenesis Holdings trades on the NASDAQ under the ticker symbol ORGO. Organogenesis Holdings stock quotes can also be displayed as NASDAQ: ORGO.

If you're new to stock investing, here's how to buy Organogenesis Holdings stock.

What is the 52 week high and low for Organogenesis Holdings (NASDAQ: ORGO)?

(NASDAQ: ORGO) Organogenesis Holdings's 52-week high was $7.08, and its 52-week low was $2.04. It is currently -65.66% from its 52-week high and 19.12% from its 52-week low.

How much is Organogenesis Holdings stock worth today?

(NASDAQ: ORGO) Organogenesis Holdings currently has 128,674,548 outstanding shares. With Organogenesis Holdings stock trading at $2.43 per share, the total value of Organogenesis Holdings stock (market capitalization) is $312.68M.

Organogenesis Holdings stock was originally listed at a price of $9.75 in Jan 5, 2017. If you had invested in Organogenesis Holdings stock at $9.75, your return over the last 9 years would have been -75.08%, for an annualized return of -14.3% (not including any dividends or dividend reinvestments).

How much is Organogenesis Holdings's stock price per share?

(NASDAQ: ORGO) Organogenesis Holdings stock price per share is $2.43 today (as of Jun 26, 2026).

What is Organogenesis Holdings's Market Cap?

(NASDAQ: ORGO) Organogenesis Holdings's market cap is $312.68M, as of Jun 30, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Organogenesis Holdings's market cap is calculated by multiplying ORGO's current stock price of $2.43 by ORGO's total outstanding shares of 128,674,548.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.